anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Treatment efficacy may differ among patients with nasopharyngeal carcinoma (NPC) at similar tumor-node-metastasis stages. Moreover, end-of-treatment tumor regression is a reliable indicator of treatment sensitivity. This study aimed to investigate whether quantitative dual-energy computed tomography (DECT) parameters could predict sensitivity to neck-lymph node radiotherapy in patients with NPC.
METHODS: Overall, 388 lymph nodes were collected from 98 patients with NPC who underwent pretreatment DECT. The patients were divided into complete response (CR) and partial response (PR) groups. Clinical characteristics and quantitative DECT parameters were compared between the groups, and the optimal predictive ability of each parameter was determined using receiver operating characteristic (ROC) analysis. A nomogram prediction model was constructed and validated using univariate and binary logistic regression.
RESULTS: DECT parameters were higher in the CR group than in the PR group. The iodine concentration (IC), normalized IC, Mix-0.6, spectral Hounsfield unit curve slope, effective atomic number, and virtual monoenergetic images were significantly different between the groups. The area under the ROC curve of the DECT parameters was 0.73-0.77. Based on the binary logistic regression, a column chart was constructed using 10 predictive factors, including age, sex, N stage, maximum lymph node diameter, arterial phase NIC, venous phase NIC, λHU and spectral Hounsfield units at 70 keV. The area under the ROC curve value of the constructed model was 0.813, with a sensitivity and specificity of 85.6% and 81.3%, respectively.
CONCLUSION: Quantitative DECT parameters could effectively predict the sensitivity of NPC to radiotherapy. Therefore, DECT parameters and NPC clinical features can be combined to construct a nomogram with high predictive power and used as a clinical analytical tool.
PURPOSE:To obtain a remedy for gastrointestinal diseases showing excellent medicinal effects on gastritis, enteritis, gastric ulcer and duodenal ulcer, containing an essence extracted from Glechoma hederacea L. and Licorice root as an active ingredient. CONSTITUTION:3-30pts.wt. Glechoma hederacea L. (name of crude drug: Glechoma herba) is blended with 2.5-25pts.wt. Licorice root (name of crude drug: Glycyrrhiza glabra L.) and boiled with 300-900pts.wt. water to exude active ingredients of the crude drugs. The exuded solution is evaporated and concentrated until the amount of water becomes <=half-one-sixth and pharmaceutically manufactured to give the aimed substance. The substance can be prepared into a dosage form such as aqueous solution, powder, granule, pill, tablet or capsule. The substance is preferably formed into granule. High-purity water such as distilled water or deionized water is preferably used as water as an exuding agent.
Prior research suggests that certain areas of the brain are receptive to chemicals like those found in the cannabis (marijuana) plant, known as cannabinoids, and that these regions may be involved in anxiety disorders and OCD. More recent data shows that synthetic drugs that target these systems may be helpful in conditions related to OCD like anxiety disorders and Tourette's syndrome. Thus, these substances could also possibly be useful to treat OCD symptoms. However, to date there has been little research regarding the role of cannabinoids in OCD.

The purpose of this study is to examine the effects of different cannabinoids on OCD symptoms in humans. To accomplish this in a laboratory setting, patients with OCD who are also occasional cannabis users will receive different combinations of two of the most well-studied cannabinoids, delta-9-tetrahydrocannabinol (THC, the main psychoactive component in cannabis) and cannabidiol (CBD, another component of the cannabis plant). We will then measure acute effects on OCD symptoms, anxiety, intoxication, and cardiovascular outcomes (i.e. blood pressure and heart rate).
###  Candesartan Cilexetil

Total plasma clearance of candesartan is 0.37 mL/min/kg, with a renal clearance of 0.19 mL/min/kg. When candesartan is administered orally, about 26% of the dose is excreted unchanged in urine. Following an oral dose of 14C-labeled candesartan cilexetil, approximately 33% of radioactivity is recovered in urine and approximately 67% in feces. Following an intravenous dose of 14C-labeled candesartan, approximately 59% of radioactivity is recovered in urine and approximately 36% in feces. Biliary excretion contributes to the elimination of candesartan. 

###  Hydrochlorothiazide

Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. At least 61% of the oral dose is eliminated unchanged within 24 hours.
A stable composition of vitamin in a gelatin-urea medium is obtained by blending gelatin, urea and water at 0 DEG  C. to 80 DEG  C. until a uniform dispersion is obtained, admixing said dispersion with said vitamin and homogenizing, if desired, the resulting mixture until a uniform emulsion is obtained.  (By the term "vitamin" used herein is meant any or all of the well-known oil-soluble vitamins and their vitamin-active, pharmaceutically-acceptable salts and esters, whether prepared synthetically or obtained from natural sources.)  The obtained emulsion may be dehydrated by heating at 40 DEG  C. to 100 DEG  C. under reduced pressure and the resulting solid reduced to any desired particle size.  Alternatively, the emulsion may be blended at 0 DEG  C. to 90 DEG  C. with an inert, adsorbent carrier until granules are obtained to form a free-flowing, water-dispersible, oxygen-stable, dry adsorbate of vitamin.  Suitable adsorbents include soy flour, corn flour, rice flour, wheat flour, gelatin, lactose, mannitol and diatomaceous earth.  In the preparation of the emulsion, it is preferable to remove the materials employed from contact with oxygen, and when it is desired to convert the emulsion to the dehydrated or adsorbate form it is advantageous to add a plasticizer to the emulsion, e.g. glucose, corn syrup, propylene glycol or honey. Bacteriostats, e.g. zinc sulphate; yeast and mould inhibitors, e.g. sorbic acid; antirancidity and chelating agents, e.g. citric acid; and anti-oxidants may also be added to the emulsion.  The dehydrated and adsorbed emulsions may be treated according to the method described in Specification 993,138 to render them insoluble in water and gastric juice but soluble in intestinal fluid.  This may be achieved by adding to the emulsion a substance such as formaldehyde, glyoxal, dihydroxy-acetone or acetaldehyde.  Specified vitamins for use in the invention are Vitamin A, Vitamin A palmitate, Vitamin A acetate and Vitamins D, E and K.  The stable vitamin preparations of the invention may be employed in the preparation of stable multi-vitamin compositions, e.g. by combining with water-soluble vitamins and minerals, or may be incorporated in foods and animal feeds.ALSO:In food or animal feed is incorporated a stable vitamin composition in which the vitamin is dispersed in a gelatin-urea medium.  ("Vitamin" is any or all of the oil-soluble vitamins and their vitamin-active, pharmaceutically-acceptable salts and esters, synthetic or from natural sources.  Specified are Vitamin A, Vitamin A palmitate, Vitamin A acetate and Vitamins D, E and K).  The compositions in emulsion form may be granulated by drying and comminuting or by mixing with a carrier such as a cereal flour, soy flour, lactose or diatomaceous earth.  A plasticizer for gelatin, e.g. glucose, corn syrup, honey or propylene glycol may be incorporated in the composition. Specification 993,138 is referred to.
A data management system for managing data acquired during medical procedures is disclosed. The data management system may include a centralized database and/or a plurality of databases storing procedure records. Each of the procedure records comprises data acquired by a data acquisition system during a medical procedure performed on a specific patient. The data management system enables users to access, search and perform analytics on data in the databases. The system may further include a blockchain configured to render immutable the data in the centralized database and databases. The data management system may include a centralized data access system enabling users to access the plurality of databases even when each of the databases are operated by different healthcare providers and when the procedure records in the databases are owned by the different owners. The data acquisition system may be part of a portable-surgical-system for performing surgery in the field.
Four ascending dose levels of Aom0319 (n=24) for intravenous injection for once. Dosage day is Day 1.
Improved pulmonary embolism (PE) detection may be obtained through computer aided-diagnosis. In particular, PE detection may be accomplished through patient-level diagnosis, embolus-level detection, or a combination of the two. Patient-level diagnosis operates to quickly exclude non-PE patients and dispatch PE-patients to treatment. Embolus-level detection operates to localize individual emboli to support personalized medicine via risk stratification. Multiple instance-based learning (MIBL) classification at the patient level explores the key observation that once any TP candidate of a patient is classified as positive, the patient is identified as PE positive. That is, MIBL focuses on correct classification of patients rather than individual candidates, to effectively and rapidly distinguish between PE patients and non-PE patients.
BACKGROUND: Mortality prognostic tools exist to aid in shared decision making with kidney failure patients but are underutilized. This study aimed to elucidate nephrology providers' practice patterns and understand barriers to prognostic tool use.
METHODS: Nephrology providers (8 physicians and 2 nurse practitioners) at an academic medical center underwent semi-structured interviews regarding their experience and perspective on the utility of mortality prognostic tools. Common themes were identified independently by 2 reviewers using grounded theory. Three six-month mortality prognostic tools were applied to the 279 prevalent dialysis patients that the interviewed providers care for. The C statistic was calculated for each tool via logistic regression and subsequent ROC analysis. Nephrology providers reviewed the performance of the prognostication tools in their own patient population. A post interview reassessed perspectives and any change in attitudes regarding the tools.
RESULTS: Nephrology providers did not use these mortality prognostic tools in their practice. Key barriers identified were provider concern that the tools were not generalizable to their patients, providers' trust in their own clinical judgement over that of a prognostic tool, time constraints, and lack of knowledge about the data behind these tools. When re-interviewed with the results of the three prognostic tools in their patients, providers thought the tools performed as expected, but still did not intend to use the tools in their practice. They reported that these tools are good for populations, but not individual patients. The providers preferred to use clinical gestalt for prognostication.
CONCLUSION: Although several well validated prognostic tools are available for predicting mortality, the nephrology providers studied do not use them in routine practice, even after an educational intervention. Other approaches should be explored to help incorporate prognostication in shared-decision-making for patients receiving dialysis.
After the carious tissue was removed and the endodontic cavity was opened, isolation was provided with a rubber-dam. After the canal length was determined with the Apex locater, the canals were prepared using Ni-Ti endodontic rotary instrument files at the torque value recommended by the manufacturer in an endodontic motor. A total of 5 ml of 1% NaOCl was washed for each canal, with 2 ml between each pecking movement of the files. The final washing of the channels was carried out using 5 ml of saline at room temperature.After the canals were dried with the help of a paper cone, the canals were filled by injecting iodoform and calcium hydroxide-containing canals. Then the restoration was completed with compomer. Following the restoration in the LLLT group, the diode laser was activated in biostimulation mode for a total of 1 minute, 30 seconds in the buccal and lingual/palatal regions at the root apex.
The present invention discloses a method for producing polystictus glycopeptides, which aims at providing a convenient method with low cost for producing polystictus glycopeptides. The method provided by the present invention basically comprises the following steps: firstly, wild polystictus fruiting bodies are pulverized, and water with the content of 5 to 15 volume times of wild polystictus fruiting bodies is added to the pulverized wild polystictus fruiting bodies; ammonia water is then used for regulating a pH value into 10 to 14; secondly, the pulverized wild polystictus fruiting bodies added with water are heated, are slightly boiled for 1 to 3 hours, and then are filtered by 100 meshes to 140 meshes; filter liquor is collected, namely that extraction liquor is collected; thirdly, first step and second step are carried out to residues obtained in second step once or twice; fourthly, the extraction liquor in second step and the extraction liquor in third step are merged, and crude extract of polystictus glycopeptides is obtained; fifthly, the crude extract is refined, and polystictus glycopeptide products are obtained. Wild resources are utilized by the present invention, and a pH method is used for extracting polystictus glycopeptides. The production cost of the present invention is low. The produced polystictus glycopeptides have high content of effective components of polysaccharide proteins, and the activity of the polystictus glycopeptides is not damaged. Byproducts or chemical pollution in the process of fermentation is reduced, and the anticancer effect of the polystictus glycopeptides is obvious.
Magneto-laser therapy is a synergistic action of a slowly changing magnetic field generated by the Viofor JPS apparatus (Med \& Life, Poland) and a low-energy laser with infrared wavelength of 808 \[nm\] (max. power 300 mW) was applied. The dose was set to increase from 3,0 J/cm2 to 5,0 J/cm2 and the total dose applied per each patient from this subgroup was 40 J/cm2. Formative procedures within the masseter muscle, duration of the session amounted to 12 minutes. Physiotherapy treatment of the masseter muscles for a period of 10 days.
A computerized alert will be deployed through the electronic health record. The alert will trigger when a provider orders platelet transfusion above a threshold supported by current guidelines. The alert will provide information on current evidence and give the provider the option to cancel the order or proceed. The alert will not be triggered in procedural areas such as the operating room or as part of any emergency orders to prevent any delays to urgent patient care.

The proposed project will evaluate this alert by randomizing its implementation by patient chart. The investigators will observe the prevalence of this alert and its impact on ordering practices for the next 3 months. For patient charts randomized not to receive the intervention, the providers will not receive any alerts, but the analytics tool will record if the alert would have been triggered and the pertinent clinical information. After a period of three months, the investigators will review patient and provider information through analytics tools, assessing differences in platelet usage between the patients whose charts showed the alerts vs. those (control) patient charts not showing alerts.
BACKGROUND: Hepatic ischemia/reperfusion (I/R) injury is a major cause of complications in clinical liver surgery. AXL receptor tyrosine kinase (AXL) is a member of the TAM receptor tyrosine kinase family (TYRO3, AXL, and MERTK). Our previous study has shown that AXL expression was markedly upregulated in liver transplantation patients. However, the underlying mechanism of AXL in hepatic I/R injury remains unclear.
METHODS: A mouse liver warm I/R model and a primary hepatocyte hypoxia/reoxygenation model were established to investigate the role of AXL activation and ferroptosis in hepatic I/R injury by pretreating with recombinant mouse growth arrest-specific protein 6 (AXL activator) or R428 (AXL inhibitor). Moreover, we used LY294002 (phosphatidylinositol 3-kinase [PI3K] inhibitor) to evaluate the relationship between the PI3K/AKT (the Ser and Thr kinase AKT) pathway and ferroptosis in hepatic I/R injury.
RESULTS: Hepatic I/R injury decreased phosphorylation AXL expression and enhanced ferroptosis in liver transplantation patients and hepatic I/R-subjected mice. AXL activation attenuated lipid peroxidation and ferroptosis in hepatic I/R injury in vivo and in vitro. Inhibition of AXL activation exacerbated liver pathological damage and liver dysfunction, as well as iron accumulation and lipid peroxidation in hepatic I/R injury. Mechanistically, activated growth arrest-specific protein 6/AXL and its downstream PI3K/AKT signaling pathway inhibited ferroptosis during hepatic I/R injury.
CONCLUSIONS: AXL activation protects against hepatic I/R injury by preventing ferroptosis through the PI3K/AKT pathway. This study is the first investigation on the AXL receptor and ferroptosis, and activating AXL to mitigate ferroptosis may be an innovative therapeutic strategy to combat hepatic I/R injury.
Latinos are the fastest growing ethnic group in the US and are disproportionately impacted by chronic conditions (e.g., overweight/obesity, diabetes) that can be mitigated by physical activity. While evidence-based programs are available to improve physical activity, dissemination is constrained by reliance on costly, limited resources. Short message service (SMS or text messaging) has strong potential as an intervention medium for Latinos, as they are dominant users of mobile phones and text messaging, including those with limited literacy and computer skills. The investigators propose to develop a personalized, culturally-congruent and interactive SMS program to promote the adoption and maintenance of physical activity for overweight, underactive Latino adults and test it for comparable efficacy to an evidence-based telephone-based advising program that has been used successfully with Latinos. Grounded in Social Cognitive and Self-Determination Theories, both programs will include a core set of self-regulatory skill building, social support, and autonomous motivation enhancement, and will be tailored for cultural, linguistic and literacy appropriateness. Randomized at the individual level, 376 sedentary, overweight Latinos ages 45 years and older will be assigned to one of three arms: the SMS-delivered physical activity program, the Human-delivered physical activity program, or an attention-control arm of SMS-delivered basic healthful nutrition advice. They will receive their assigned program for 12 months, and then will be followed for a 6-month maintenance phase, with a final assessment at 18 months. Analyses will determine if the two physical activity programs result in equivalent efficacy in adoption and maintenance of clinically meaningful physical activity increases, and superiority over the attention-control arm at 12 and 18 months. The two physical activity interventions will also be compared for equivalency in prevention of weight gain and reduction in abdominal adiposity. The investigators will explore the relative costs of the programs to determine which program increases physical activity for a lower cost. While health promotion programs delivered by professional staff may be more expensive than those delivered electronically, it is unclear if the automated version can produce more cost-efficient outcomes (i.e., comparable improvements in outcomes for significantly reduced cost). This study will determine if SMS is equivalent in efficacy to the traditional human-delivery channel in increasing physical activity and preventing weight gain, and if it results in a more cost-efficient program. If achieved, this research can significantly reduce health disparities associated with physical activity for Latinos by providing an efficacious, tailored and culturally appropriate program poised for widespread dissemination and rapid uptake.
PROBLEM TO BE SOLVED: To obtain a medicine, a beverage, a food and a cosmetic excellent in safety, having antiinflammatory action, antiallergic action and anti-atopic dermatitis action free from adverse effects even in the case of long-term chronic use, by using a specific tea extract as an active ingredient. SOLUTION: This antiallergic agent comprises an oolong tea extract obtained by extracting an oolong tea with an aqueous solvent. In the extraction, the ratio of the solvent to the oolong tea is 2-1,000 pts.wt., especially about 5-100 pts.wt. to 1 pt.wt. of the oolong tea. The antiallergic agent, antiinflammatory agent or anti-atopic dermatitis agent is effective for preventing and treating diseases based on especially IV type allergic reactions. The agent can prevent and alleviate inflammations and swelling of throat followed by cold, pollinosis, cough, etc.
The present invention relates to an edible bamboo charcoal and the manufacturing method which is made through three stages and seven steps. The first stage: the selection of raw bamboo should be monitored. The stage involves two steps: firstly, the soil of bamboo original existing areas should be detected and controlled, in particular to the content of heavy metal which can not be over a certain standard; secondly, the raw bamboo must be one-year-life south bamboo, and the parts of bamboo shoot and root which is lower than 500mm should be removed, and the outer of bamboo and bamboo reed must be sampled and tested to make the raw materials enter into kiln to meet the standard. The second stage: carbonization and steam reactivation which contains four steps: first, the fresh bamboo with moisture content of 30-40 percent encased into stainless run kiln and steamed with smoke to dehydrate for 3-6 days; second, the dehydrated fresh bamboo is distilled and carbonized; third, the temperatureof the kiln is increased to 500-800 centigrade, and the edible bamboo is refined and sprayed with water to reactivate, and the time is about 1 hour; four, materials are reclaimed after the kiln is closed 2 days. The third stage: aseptic product processing, which is the last step, and contains the procedures of bamboo charcoal crushing, thinning and sterilizing and aseptic packaging. When edible bamboo charcoal produced by aseptic special equipment reaches to 1000-1500 meshes, encapsulation and sampling inspection for a record should be made. The edible bamboo charcoal produced by the method, the content of heavy metal is much lower than national hygienic standard. The finished edible bamboo charcoal can be eaten directly after being manufactured into capsule, and also can be added into the rice or wheat flour finished product based on various ratios, which can make the excellent characteristics of activated bamboo charcoal melt into various foods.